LundLHEdwardsLBKucheryavayaAY. The Registry of the International Society for Heart and Lung Transplantation: thirty-second official adult heart transplant report—2015; focus theme: Early Graft Failure. J Heart Lung Transplant. 2015;34(10):1244–1254. doi:10.1016/j.healun.2015.08.003.
2.
Colvin-AdamsMAgnihotriA. Cardiac allograft vasculopathy: current knowledge and future direction. Clin Transplant. 2011;25(2):175–184. doi:10.1111/j.1399-0012.2010.01307.x.
3.
JansenMAOttenHGde WegerRAHuibersMM. Immunological and fibrotic mechanisms in cardiac allograft vasculopathy. Transplantation. 2015;99(12):2467–2475. doi:10.1097/TP.000000000000848.
4.
LeeMSYangTKandzariD. Long-term clinical outcomes in patients treated with drug-eluting compared to bare-metal stents for the treatment of transplant coronary artery disease. Catheter Cardiovasc Interv. 2012;80(4):533–538. doi:10.1002/ccd.23379.
5.
PighiMTomaiFPetroliniA. Everolimus-eluting bioresorbable vascular scaffold system in the treatment of cardiac allograft vasculopathy: the CART (Cardiac Allograft Reparative Therapy) Prospective Multicenter Pilot Study. J Cardiovasc Transl Res. 2016;9(1):40–48. doi:10.1007/s12265-015-9665-x.
